AKT、ATR与Notch抑制剂增强腺样囊性癌临床前模型放疗敏感性
该研究利用cBioPortal进行基因组与生存分析,并在ACC肿瘤、PDX及细胞系中评估MYB、AKT、ATR、NOTCH及NFIB表达;发现这些基因在ACC中过表达,且ATR、AKT、MYB、NFIB改变患者总生存较差;ATR、AKT和Notch抑制剂可增强UM-HACC2A细胞对放疗的敏感性。
要点
- MYB、ATR、AKT1、Notch1/2、NFIB在ACC肿瘤、PDX及细胞系中过表达。
- ATR、AKT、MYB、NFIB改变与ACC患者总生存较差相关。
- ATR、AKT和Notch抑制剂可增强ACC临床前模型的放疗敏感性。
核心结论
- ATR、AKT和Notch抑制剂可增强ACC临床前模型的放疗敏感性。
研究设计与样本
- 使用cBioPortal进行基因组和生存分析,并通过RNA-seq、qRT-PCR和western blot评估表达。
- 采用克隆形成实验评估放疗增敏,通过γH2AX和RAD51焦点实验检测DNA损伤效应。
主要发现
- MYB、ATR、AKT1、Notch1、Notch2和NFIB在ACC肿瘤、PDX和细胞系中过表达。
- ATR、AKT、MYB和NFIB改变与ACC患者总生存较差相关。
- ATR、AKT和Notch抑制剂使UM-HACC2A细胞对放疗敏感。
- 药物与放疗联合降低靶基因mRNA表达。
临床怎么用
- 在ACC临床前模型中,ATR、AKT和Notch抑制剂联合放疗可增强放疗效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adenoid Cystic Carcinoma (ACC) is a rare and lethal type of head and neck cancer. Standard therapy involves surgery followed by radiation therapy. The majority of ACC has MYB overexpression and MYB-NFIB gene fusions, while Notch mutations are associated with aggressive behavior. Targeted therapies against these drivers or their downstream targets have been incompletely explored, especially in combination with radiation. METHODS: cBioPortal was used for genomic and survival analyses. MYB, AKT, ATR, NOTCH, and NFIB expression was assessed via RNA-seq, qRT-PCR, and western blot. Radiation sensitization was evaluated by clonogenic assays while the effect on DNA damage was tested using γH2AX and RAD51 foci assays. RESULTS: MYB, ATR, AKT1, Notch1, Notch2, and NFIB are overexpressed in ACC tumors, PDX, and cell lines. ACC patients with ATR, AKT, MYB, and NFIB alterations have poor overall survival. ATR, AKT, and Notch inhibitors sensitized UM-HACC2A cells to radiation. Drugs and radiation combination reduced target mRNA expression. CONCLUSION: ATR, AKT, and Notch inhibitors radiosensitize a preclinical model of ACC.
引用
- Thoidingjam S, Sriramulu S, Muratoglu AH, et al. AKT, ATR, and Notch Inhibitors Radiosensitize a Preclinical Model of Adenoid Cystic Carcinoma. Head Neck. 2026. PMID: 41923464. doi:10.1002/hed.70253
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。